Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition Read More September 18, 2025
Behind “Rise of Malingering” in ER Psychiatry: Why Better Patient Classification Matters Read More September 18, 2025